artenimol has been researched along with Carcinoma, Non-Small Cell Lung in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, C; Li, Y; Lu, H; Tang, J; Tang, Y; Wang, Y; Xiao, X; Yang, J; Zhang, Y; Zhong, Z | 1 |
| Lai, XY; Shi, YM; Zhou, MM | 1 |
| Chen, LW; Hu, BQ; Huang, JF; Liu, Y; Niu, K; Wang, NN; Zhou, J | 1 |
| Kumar, R; Panda, AK; Saneja, A | 1 |
| Cai, X; Cao, P; Chaib, I; Miao, J; Molina-Vila, MA; Rosell, R; Sun, R; Wang, S | 1 |
| Jin, Z; Li, Y; Wang, H; Wang, Y; Xiao, X; Yang, J; Yue, F; Zhang, Y; Zhou, Q; Zhou, S | 1 |
| Cao, Y; Jiang, AY; Jiang, XF; Jin, H; Wang, H; Wu, Y | 1 |
| An, Z; Li, P; Liu, J; Qi, M; Qi, Y; Shao, H; Wu, H; Xiao, H; Yan, X; Yang, W; Zhan, Y | 1 |
| Cai, FY; Fu, M; Gong, XQ; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Tang, W; Yao, XM | 1 |
| Dai, L; Deng, L; He, J; Lei, J; Li, D; Liu, J; Wang, L | 1 |
| Chen, YQ; Gao, J; Geng, GJ; Jiang, J; Li, CL; Li, N; Liu, Y; Luo, XY; Mi, YJ; Yu, XY; Zou, ZZ | 1 |
| Hu, M; Li, F; Liu, W; Liu, Y; Liu, Z; Lu, L; Ou, R; Tong, Y; Wu, J; Zhang, G; Zheng, H; Zheng, L | 1 |
| Fei, J; Li, J; Shen, R; Wang, Q; Ye, D | 1 |
| An, H; Cai, C; Gao, J; Geng, G; Jiang, J; Li, N; Liu, H; Mi, Y; Shen, D; Wu, X; Yang, S; Yu, X; Zheng, L | 1 |
14 other study(ies) available for artenimol and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer.
Topics: Animals; Artemisinins; Artesunate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Glucose; Glycolysis; Lung Neoplasms; Mice; Proto-Oncogene Proteins c-myc; Signal Transduction | 2022 |
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer.
Topics: Animals; Artemisinins; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms | 2023 |
An Annexin V-FITC-Propidium Iodide-Based Method for Detecting Apoptosis in a Non-Small Cell Lung Cancer Cell Line.
Topics: A549 Cells; Annexin A5; Apoptosis; Artemisinins; Carcinoma, Non-Small-Cell Lung; Fluorescein-5-isothiocyanate; Humans; Lung Neoplasms; Propidium | 2021 |
Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Heme; Heme Oxygenase-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
Topics: Animals; Apoptosis; Artemisinins; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Network Pharmacology; Protein Interaction Maps; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin B1; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
Topics: A549 Cells; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; STAT3 Transcription Factor; Sulfonamides; Survivin; Xenograft Model Antitumor Assays | 2018 |
Development of R
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Drug Liberation; Epirubicin; Humans; Lipid Bilayers; Liposomes; Lung Neoplasms; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2019 |
Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Artemisinins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Polyethylene Glycols; Solubility; Structure-Activity Relationship; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells.
Topics: Adenosine Triphosphate; Apoptosis; Artemisinins; Biological Transport; Carcinoma, Non-Small-Cell Lung; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Drug Synergism; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Lung Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.
Topics: A549 Cells; Animals; Antimalarials; Artemisinins; Artesunate; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; RNA Interference; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
Topics: A549 Cells; Animals; Antimalarials; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ribonucleases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis.
Topics: Animals; Antimalarials; Artemisinins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Female; Glucose Transporter Type 1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B | 2016 |